IX Biopharma in advanced talks on US WaferiX joint venture with GLD, Orion

  • IX Biopharma moved closer to a proposed US joint venture with GLD Partners and Orion Specialty Labs to commercialize its WaferiX sublingual drug delivery platform.
  • Talks shifted from a manufacturing and commercialization arrangement outlined in a Nov. 10, 2025 term sheet to a structure that would fold Orion into newly formed holding company Ligo Pharma, leaving GLD as a co-shareholder.
  • Consumer-facing assets, including about 40 WaferiX-based compounded formulations and a direct-to-consumer telehealth platform under development, are being consolidated under Ligo ahead of any definitive joint venture agreements.
  • Wafermine regulatory assets and US Department of Defense contract obligations stay with IX Biopharma under restructuring.
  • Company said it will disclose commercial and funding terms once definitive agreements are signed.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IX Biopharma Ltd. published the original content used to generate this news brief via Singapore Exchange Limited (SGX) (Ref. ID: FMCPS3EGS4EDYWS4) on May 10, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.